An Open-label Comparative Study of the Pharmacokinetics, Safety and Tolerability of ZD4054 following a 10 mg Single Oral Dose of ZD4054 to Healthy Subjects and to Subjects with Mild, Moderate and Severe Hepatic Impairment

Trial Profile

An Open-label Comparative Study of the Pharmacokinetics, Safety and Tolerability of ZD4054 following a 10 mg Single Oral Dose of ZD4054 to Healthy Subjects and to Subjects with Mild, Moderate and Severe Hepatic Impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Zibotentan (Primary)
  • Indications Breast cancer; Colorectal cancer; Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 06 Mar 2009 Actual end date reported as 1 Mar 09 by ClinicalTrials.gov.
    • 06 Mar 2009 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 10 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top